271 related articles for article (PubMed ID: 29504446)
21. B cell activation through CD40 and IL4R ligation modulates the response of chronic lymphocytic leukaemia cells to BAFF and APRIL.
Ferrer G; Bosch R; Hodgson K; Tejero R; Roué G; Colomer D; Montserrat E; Moreno C
Br J Haematol; 2014 Feb; 164(4):570-8. PubMed ID: 24245956
[TBL] [Abstract][Full Text] [Related]
22. Multiple Myeloma, Targeting B-Cell Maturation Antigen With Chimeric Antigen Receptor T-Cells.
Shah UA; Smith EL
Cancer J; 2019; 25(3):208-216. PubMed ID: 31135528
[TBL] [Abstract][Full Text] [Related]
23. Polymorphisms in genes of the BAFF/APRIL system may constitute risk factors of B-CLL--a preliminary study on a Polish population.
Jasek M; Wagner M; Sobczynski M; Wolowiec D; Kuliczkowski K; Woszczyk D; Kielbinski M; Kusnierczyk P; Frydecka I; Karabon L
Tissue Antigens; 2015 Oct; 86(4):279-84. PubMed ID: 26268376
[TBL] [Abstract][Full Text] [Related]
24. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
Feng D; Sun J
Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
[TBL] [Abstract][Full Text] [Related]
25. Chimeric antigen receptor T cell targeting B cell maturation antigen immunotherapy is promising for multiple myeloma.
Ma T; Shi J; Liu H
Ann Hematol; 2019 Apr; 98(4):813-822. PubMed ID: 30693373
[TBL] [Abstract][Full Text] [Related]
26. Mass spectrometry-based identification of a B-cell maturation antigen-derived T-cell epitope for antigen-specific immunotherapy of multiple myeloma.
Bilich T; Nelde A; Bauer J; Walz S; Roerden M; Salih HR; Weisel K; Besemer B; Marcu A; Lübke M; Schuhmacher J; Neidert MC; Rammensee HG; Stevanović S; Walz JS
Blood Cancer J; 2020 Feb; 10(2):24. PubMed ID: 32111817
[TBL] [Abstract][Full Text] [Related]
27. B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma.
Eckhert E; Hewitt R; Liedtke M
Immunotherapy; 2019 Jun; 11(9):801-811. PubMed ID: 31094254
[TBL] [Abstract][Full Text] [Related]
28. B-cell maturation antigen-specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives.
Sellner L; Fan F; Giesen N; Schubert ML; Goldschmidt H; Müller-Tidow C; Dreger P; Raab MS; Schmitt M
Int J Cancer; 2020 Oct; 147(8):2029-2041. PubMed ID: 32270481
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.
Lee L; Bounds D; Paterson J; Herledan G; Sully K; Seestaller-Wehr LM; Fieles WE; Tunstead J; McCahon L; Germaschewski FM; Mayes PA; Craigen JL; Rodriguez-Justo M; Yong KL
Br J Haematol; 2016 Sep; 174(6):911-22. PubMed ID: 27313079
[TBL] [Abstract][Full Text] [Related]
30. Increased BCMA expression in lupus marks activated B cells, and BCMA receptor engagement enhances the response to TLR9 stimulation.
Kim J; Gross JA; Dillon SR; Min JK; Elkon KB
Autoimmunity; 2011 Mar; 44(2):69-81. PubMed ID: 21250838
[TBL] [Abstract][Full Text] [Related]
31. Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
D'Agostino M; Raje N
Leukemia; 2020 Jan; 34(1):21-34. PubMed ID: 31780814
[TBL] [Abstract][Full Text] [Related]
32. B-cell maturation antigen expression across hematologic cancers: a systematic literature review.
Dogan A; Siegel D; Tran N; Fu A; Fowler J; Belani R; Landgren O
Blood Cancer J; 2020 Jun; 10(6):73. PubMed ID: 32606424
[TBL] [Abstract][Full Text] [Related]
33. [Advance of Research on the Immunotherapy Targeting B Cell Maration Antigen for Multiple Myeloma--Review].
Luan CY; Jian ZY; Cheng T; Chen BA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1701-1705. PubMed ID: 31607335
[TBL] [Abstract][Full Text] [Related]
34. BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them.
Rees MJ; Kumar S
Leuk Lymphoma; 2024 Mar; 65(3):287-300. PubMed ID: 38354090
[TBL] [Abstract][Full Text] [Related]
35. Novel targets for the treatment of relapsing multiple myeloma.
Giuliani N; Accardi F; Marchica V; Dalla Palma B; Storti P; Toscani D; Vicario E; Malavasi F
Expert Rev Hematol; 2019 Jul; 12(7):481-496. PubMed ID: 31125526
[No Abstract] [Full Text] [Related]
36. Quantification of B-cell maturation antigen, a target for novel chimeric antigen receptor T-cell therapy in Myeloma.
Salem DA; Maric I; Yuan CM; Liewehr DJ; Venzon DJ; Kochenderfer J; Stetler-Stevenson M
Leuk Res; 2018 Aug; 71():106-111. PubMed ID: 30053652
[TBL] [Abstract][Full Text] [Related]
37. Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8
Bae J; Samur M; Richardson P; Munshi NC; Anderson KC
Leukemia; 2019 Sep; 33(9):2208-2226. PubMed ID: 30872779
[TBL] [Abstract][Full Text] [Related]
38. Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus.
Salazar-Camarena DC; Ortiz-Lazareno PC; Cruz A; Oregon-Romero E; Machado-Contreras JR; Muñoz-Valle JF; Orozco-López M; Marín-Rosales M; Palafox-Sánchez CA
Lupus; 2016 May; 25(6):582-92. PubMed ID: 26424128
[TBL] [Abstract][Full Text] [Related]
39. Binding of B-cell maturation antigen to B-cell activating factor induces survival of multiple myeloma cells by activating Akt and JNK signaling pathways.
Shen X; Guo Y; Qi J; Shi W; Wu X; Ju S
Cell Biochem Funct; 2016 Mar; 34(2):104-10. PubMed ID: 26914861
[TBL] [Abstract][Full Text] [Related]
40. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
Cohen AD; Garfall AL; Stadtmauer EA; Melenhorst JJ; Lacey SF; Lancaster E; Vogl DT; Weiss BM; Dengel K; Nelson A; Plesa G; Chen F; Davis MM; Hwang WT; Young RM; Brogdon JL; Isaacs R; Pruteanu-Malinici I; Siegel DL; Levine BL; June CH; Milone MC
J Clin Invest; 2019 Mar; 129(6):2210-2221. PubMed ID: 30896447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]